Analyst Rating Update on Qiagen N.V. (QGEN)

Qiagen N.V. (QGEN) : The consensus on Qiagen N.V. (QGEN) based on 11 analyst recommendation on the company stock is 2.59, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst also believes that the downside risk to the stock is higher and suggests a Sell on Qiagen N.V. (QGEN).

Qiagen N.V. (QGEN) : The consensus price target for Qiagen N.V. (QGEN) is $24.71 for the short term with a standard deviation of $1.89. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $27, however, the pessimist price target for the company is $22.

Company shares have received an average consensus rating of Hold for the current week


Qiagen N.V. (NASDAQ:QGEN): The stock opened at $26.51 on Wednesday but the bulls could not build on the opening and the stock topped out at $26.67 for the day. The stock traded down to $26.47 during the day, due to lack of any buying support eventually closed down at $26.59 with a loss of -0.56% for the day. The stock had closed at $26.74 on the previous day. The total traded volume was 1,201,756 shares.

QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.